CRDL Insider Trading

12.99% of Cardiol Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Today's Range

Now: C$3.13

C$3.04

C$3.20

50 Day Range

MA: C$3.05

C$2.51

C$4.07

52 Week Range

Now: C$3.13

C$0.91

C$4.26

Volume

86,900 shs

Average Volume

150,828 shs

Market Capitalization

C$215.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Who are the company insiders with the largest holdings of Cardiol Therapeutics?: Cardiol Therapeutics' top insider investors include:
David Elsley (Director)
Guillermo Torre (Senior Officer)
Learn More about top insider investors at Cardiol Therapeutics.